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In July 2010, the World Health Organization 
(WHO) released their new guidelines on 
Antiretroviral therapy for HIV infection in adults 
and adolescents: Recommendations for a public 
health approach which were last published in 2006.  
The goals of these guidelines as outlined by WHO 
are to use the public health approach to improve 
treatment outcomes and the quality of life of people 
living with HIV.  WHO released these guidelines as 
a result of new literature addressing timing of 
st nd
treatment initiation, selection of 1  and 2  line 
treatment regimens and management of patients 
with co-infections.  This article will review these 
new recommendations in the context of the current 
literature and current treatment practices in Zambia. 
When to start therapy? 
The WHO guidelines stress avoiding death, disease 
progression and HIV transmission in determining 
when a patient should be initiated on antiretrovirals 
(ARVs) .   The  major  change  in  the i r  
recommendation for treatment initiation is to start 
antiretroviral therapy (ART) at CD4 counts <350 
3 3cells/mm  instead of <200 cells/mm .  The primary 
study cited by WHO is CIPRA HT-001, a 
randomized clinical trial in Haiti which randomized 
participants to start ART at CD4 counts of 200-350 
3cells/mm  or to defer therapy until CD4 counts were 
3<200 cells/mm .  At the interim analysis, higher 
mortality was seen in the patients that deferred ART 
and the study was terminated early.  Multiple studies 
(summarized in the table below) have shown that 
early ART initiation improves outcome measures 
such as morbidity, mortality, and immune 
reconstitution.  
Increasing evidence, including a study partially 
conducted in Zambia, suggests treatment of HIV-
infected individuals can also result in decreased 
9-11
sexual transmission of HIV.   A South African 
study published prior to the 2006 WHO update 
predicted an 11.9% reduction in annual risk of HIV 




Decrease in AIDS related events when 
ART initiated at CD4>250 cells/mm3 
  
When to Start3 Decreased all-cause mortality when 




Decreased all-cause mortality when 
ART initiated at higher CD 4 counts 
 
NA-ACCORD5 69% increase risk of death in patients 
deferring ART compared to those  
starting ART at CD4 counts of 350 -
500 cells/mm3 
 
ATHENA 6 Immune reconstitution with CD4 count 
>800 cells/mm3 more likely when 
ART initiated at higher CD4 counts 
 
HOPS cohort7,8 Early treatment initiation associated 
with higher CD4 count immune 
reconstitution 
118
Medical Journal of Zambia, Vol. 37. No. 2 (2010)
Key words: Guidelines, HIV, World Health 
Organization, antiretroviral, Zambia.
transmission if all patients with a CD4 count >200 
3
cells/mm  were initiated on treatment and a 71.8% 
reduction in annual risk of HIV transmission could 
be expected if all patients with a CD4 count of <350 
3 12
cells/mm  were started on ART.   A more recent 
study from Kenya showed a 92% reduction in HIV 
transmission when the infected individual is on ART 
with the greatest benefit seen in individuals with low 
13CD4 counts or high viral loads.   In Zambia, 68% of 
those with severe HIV disease are currently 
receiving ART based on local guidelines for 
eligibility which are similar to the previous WHO 
14guidelines.   If the greatest benefit of treatment as a 
prevention strategy is seen in individuals with low 
CD4 counts, then Zambia may be able to implement 
this strategy by achieving a higher level of ART 
coverage of these same patients.  However, further 
studies need to duplicate the results seen in Kenya to 
show true effectiveness. 
While the authors agree that currently available data 
support earlier treatment initiation, this has to be 
viewed in the context of available resources and the 
commitment of the donor community.  Medecins 
Sans Frontieres published a report in May 2010 
documenting their observations in 8 sub-Saharan 
African countries (not including Zambia) that show 
decreased donor commitments that has resulted in 
stalling of new patient enrollment.  They postulate 
that if this trend continues, implementation of WHO 
guidelines will not be possible and patients will be 
15
turned away when eligible for treatment.   This is 
particularly important in Zambia where 
international sources accounted for approximately 
14
76% of total national AIDS spending in 2006.   The 
new WHO guidelines undoubtedly will increase the 
burden of stress on a stretched Zambian health care 
system that will require continued support from 
global health care initiatives to keep up with the 
costs incurred by treating these additional patients.  
What to Start? 
The major changes in this recommendation are that 
stavudine (d4T) and abacavir (ABC) are no longer 
listed as options in the first line regimen.  A primary 
reason for this change is that d4T has an unfavorable 
side effect profile including; lipodystrophy, 
peripheral neuropathy and lactic acidosis, thus 
making other nucleoside reverse transcriptase 
inhibitor (NRTI) options more attractive for 
treatment  WHO does not mention perhaps an 
equally important reason for removing d4T from the 
st nd
1  line regimen: the inability to sequence to 2  line 
drugs after failing a d4T regimen.  When a patient 
fails on d4T, thymadine analogue mutations (TAMs) 
will begin to accumulate.  These TAMs reduce the 
activity of all other NRTIs including tenofovir 
(TDF), making them less effective or completely 
ineffective.  A study from Malawi observed multiple 
different resistance patterns with d4T use in subtype 
C virus (the predominant HIV subtype in Zambia), 
nd 16 all of which led to compromised 2  line treatment.   
Accumulation of TAMs is also an issue with AZT as 
sta 1  line regimen, making both TDF and ABC better 
stalternatives for 1  line ART from a resistance 
perspective.  Failure with either of these agents 
leads to mutations which  preserve AZT activity, 
ndallowing for effective AZT use as a fully active 2  
line agent.  
st
Abacavir (ABC) was listed as a possible agent in 1  
line ART in the prior guidelines but has been omitted 
from this recommendation without a specific 
explanation.  Abacavir is more expensive than the 
other NRTIs, and can also cause a potentially fatal 
hypersensitivity reaction in up to 5-8% of patients 
17starting this drug.   However, a strong association 
has been observed with the presence of the HLA-
B*5701 allele and risk for the hypersensitivity 
reaction, and this gene is relatively uncommon in 
sub-Saharan Africans (<1%) compared to US 
18-19
Caucasians (~8%).  The expected rate of this 
reaction in Zambia should therefore be significantly 
less than that observed in the US and Europe.  A 
more compelling argument against using ABC as a 
preferred NRTI may be the results of ACTG 5202.  
This randomized controlled trial comparing the 
efficacy and safety of TDF/FTC and ABC/3TC  
regimens revealed a shorter time to failure in the 
ABC arm if the initial viral load was >100,000 
20
copies/mL.   These results were contrary to the 
HEAT study which showed comparable viral 
suppression rates at 96 weeks for both TDF and 
21ABC based regimens irrespective of CD4 count.   
Further investigation is necessary before 
stdiscounting ABC as a 1  line drug but its higher cost 
stwill likely keep it from routine 1  line use in Zambia. 
WHO has taken a major step forward with its new 
strecommendations for 1 -line therapy.  The decision 
to remove d4T, based on its known toxicities and the 
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impact that these have on patient morbidity, 
mortality, and adherence should reap long-term 
benefits. However, they do not explicitly address the 
issue of drug sequencing, which is critical in 
ndresource limited settings so that viable 2 -line 
stoptions will remain for those who fail 1  line. 
HIV and Tuberculosis co-infection 
The major change in regards to TB co-infection is 
that WHO now recommends starting ART on all 
patients with TB.  The two diseases potentiate each 
other's course, increasing morbidity and 
22,23mortality.  Despite this knowledge, no clear 
consensus has been achieved regarding the optimal 
time to start ARVs in a patient with TB co-infection.  
Clinicians may defer treatment of HIV until after 
completion of TB treatment to minimize drug-
related toxicities, the possibility of developing 
Immune Reconstitution Inflammatory Syndrome 
(IRIS) and  drug-drug interactions (particularly the 
cytochrome p450 mediated interactions between 
rifampin and protease inhibitors which are the 
ndmainstay of 2  line treatment in Zambia).  However, 
this may place the patient at risk for developing 
concomitant opportunistic infections thereby 
24increasing morbidity and mortality.  The SAPIT 
trial, a randomized controlled trial conducted in 
South Africa, demonstrated 56% lower mortality in 
patients receiving concurrent TB/HIV treatment 
compared to those who deferred ART until after 
27
completion of anti-tuberculous therapy (ATT).   
The same study also demonstrated that the rate of 
IRIS was three times higher with concurrent 
treatment.  In Zambia, up to 60% of TB patients are 
14also HIV infected.   The authors contend that the 
risk of IRIS is outweighed by the reduction in 
mortality that would occur if Zambia adopted this 
recommendation.  The ideal timing of ART 
initiation during ATT is still an unanswered question 
that hopefully will be answered by several ongoing 
26studies (SAPIT, ACTG A5221, and CAMELIA).  
HIV and HBV co-infection 
The new recommendations from WHO regarding 
HIV and hepatitis B virus (HBV) co-infection are 
more liberal in terms of eligibility for treatment.  
The guidelines recommend that all co-infected 
individuals that require treatment for HBV infection 
should start ART but do not discuss what constitutes 
need for HBV treatment.  The literature is well 
established regarding increased liver-related deaths 
in patient with HIV disease, and the majority of 
these deaths are related to progression of either 
27,28HBV or hepatitis C virus (HCV) infection.   ART 
with activity against HBV may reduce some of 
these liver-related mortalities if patients with HBV 
co-infection are identified early and started on 
treatment before progression of liver disease.  TDF, 
FTC, and 3TC all have anti-HBV activity, so 
patients with HIV/HBV co-infection should be 
started on a regimen including TDF plus either FTC 
or 3TC.  None of the other NRTIs have anti-HBV 
activity, so using 3TC in combination with anything 
else will effectively lead to HBV monotherapy.  
This is not advised due to the rapid development of 
293TC resistance in HBV.   HBV flares have been 
reported in patients on ART once effective anti-
HBV drugs were withdrawn.  Patients receiving 
3TC but not TDF who then developed 3TC 
30resistance have also had HBV flares.   This further 
emphasizes the need for multidrug therapy for HBV 
co-infected patients. 
The exact burden of HBV disease in Zambia is 
uncertain but this recommendation encourages 
clinicians to investigate for HBV and HIV co-
infection.  Unpublished data in Zambia from 
Kapembwa et al found HBsAg to be positive in 
9.9% of HIV-positive, ART-eligible adults.  A small 
study from Kitwe found a HCV seroprevalence of 
4.1% and HBV seroprevalence of 9.3% in HIV-
31infected pregnant women not yet on HAART.   
Identifying these patients may have significant 
impact on liver-related deaths in patients living with 
st
HIV in Zambia.  The Zambia 1  line regimen 
already includes TDF and 3TC/FTC meaning that 
many patients with co-infection are being treated 
for HBV even if the clinician is unaware of the HBV 
status of the patient.  Knowing the HBV status of 
this patient will be increasingly important if a 
regimen switch is considered as withdrawal of HBV 
treatment could lead to acute hepatitis flares. 
When should ART be switched? 
Viral load testing for HIV is the ideal method for 
detecting treatment failure but may not be feasible 
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in all settings.  The WHO definition of virological 
failure is based on thresholds of viremia below 
which clinical progression has not been shown to 
occur.  The previous guidelines set 10,000 viral 
copies/ml as the threshold for failure based on the 
available literature that suggested clinical 
progression was minimal below the range of 5,000 to 
32,33
10,000 copies/ml.  If the goal of ART is 
suppression of viral replication, then any 
persistently detectable viremia would constitute 
virological failure.  Even low-level (< 1000 c/ml) 
viremia over time will lead to the accumulation of 
resistance mutations which may significantly impact 
34future treatment options for the patient;  therefore, 
we contend any detectable viremia on ART is 
unacceptable. 
Immunologic criteria are the primary method of 
determining failure in many countries including 
Zambia.  Multiple studies have shown that these 
criteria do not correlate well with true virological 
failure.  A study in Rakia, Uganda found that 11% of 
patients met WHO immunologic criteria for failure 
while 9.9% met virological criteria (2 viral loads 
>400 copies/ml) but only 2.3% of the patients met 
both immunologic and virological criteria for 
35failure.   In another cohort of 149 patients in western 
Kenya, 58% of patients classified as failing based on 
36immunologic criteria were actually not failing.   
Clearly immunologic criteria alone are not sufficient 
in determining treatment failure and WHO seems to 
address this by recommending that immunologic 
criteria be used to CONFIRM clinical failure.  This 
strategy may prevent many patients from being 
ndswitched inappropriately to 2  line ART, but it may 
also lead delayed diagnosis of treatment failure 
resulting in accumulation of significant resistance 
nd
and compromised 2 -line treatment options.  Until 
viral load technology becomes widely affordable 
and accessible, the ideal strategy for early and 
accurate diagnosis of treatment failure in resource 
limited settings remains to be determined. 
ndWhat should the 2  line regimen of ART be? 
nd
The strategy for 2  line ART continues to be 
predicated on the use of boosted protease inhibitors 
(PIs) which should be fully active in combination 
with an NRTI backbone.  WHO now recommends 
atazanavir (ATV) boosted with ritonavir (r) or 
boosted lopinavir (LPV/r) as a preferred PI.    
Boosted ATV requires only 100mg of ritonavir as 
opposed to the 200mg daily used with LPV.  
Atazanavir thus has the benefit of being a once/day 
medication with fewer GI side effects, less 
metabolic toxicity and lower pill count while 
37providing comparable efficacy to LPV/r.   In many 
ndways, an ATV based 2  line regimen is preferable but 
likely cost-prohibitive in a resource limited setting.  
A cost analysis of the CASTLE study demonstrated 
that the use of a Lop/r saved USD 25,518 over 5 
years compared to ATV/r. Additionally, observation 
of indirect hyperbilirubinemia (the major side effect 
of ATV) may be mistaken for liver disease in a 
setting where appropriate hepatic evaluation may be 
difficult to perform.  A lopinavir based regimen will 
nd
likely continue to be the mainstay of 2  line 
treatment in sub-Saharan Africa. 
ndThe rationale for specific NRTIs in 2  line ART is 
sound when considering the mutations with failure 
stof the 1  line regimen.  As mentioned before, d4T 
ndand AZT use may result in TAMs making 2  line 
therapy less effective.  However, if TDF (or ABC) is 
stused in the 1 -line regimen, AZT will remain fully 
ndactive in the 2 -line regimen.  The Zambian 
guidelines wisely incorporated this approach in their 
2007 revision. 
rd
What should the 3  line regimen be? 
W H O  i s  p a r t i c u l a r l y  v a g u e  i n  t h e i r  
rdrecommendations for 3  line regimens and this is 
appropriate given the financial implications of 
rdrecommending a particular drug for 3  line or 
salvage therapy.  When and how to use third line 
regimens should be determined at the national level 
with local experts determining the feasibility of 
obtaining agents from the new class of co-receptor 
antagonists (i.e. maraviroc) and integrase inhibitors 
(i.e. raltegravir) or newer ARV medications from 
older classes (i.e. the protease inhibitor darunavir 
and the newer generation NNRTI etravirine).  In 
addition to the significant cost of these drugs, 
appropriate management of ARV-experienced 
patients will also require development of labs 
capable of performing viral load and genotypic 
resistance testing.  Individual countries will have to 
decide how best to manage this increasingly 
common problem as more and more patients are 
being put on ART.
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CONCLUSION 
Many countries in sub-Saharan Africa including 
Zambia have a high prevalence of HIV infection 
while often lacking sufficient resources to deal with 
this pandemic.  The WHO guidelines look to address 
this issue of providing appropriate HIV care in the 
context of resource-limited settings.  They take a 
major step forward in recommending that all 
3
patients with a CD4 count below 350 cells/mm  be 
initiated on ART.  The implications of this are 
substantial with increased need for resources and 
healthcare manpower.  However, this strategy in the 
long-term should decrease hospital admissions for 
OIs and other HIV-related illnesses which currently 
overburden most hospitals in Zambia.  The other 
stmajor change is dropping d4T from the list of 1  line 
agents for ART.  This recommendation will have 
significant impact on patient quality of life and 
further enforces the concept that patients in 
resource-limited countries should be eligible for the 
same quality of therapy as those in resource-rich 
countries. 
Issues regarding patients with co-morbidities are 
less clear although most clinicians likely agree with 
WHO recommendations to initiate ART in all 
patients with TB.  With mounting evidence of liver-
related deaths in HIV-positive individuals, screening 
for HBV co-infection will be increasingly important 
for preventable liver-related deaths.  Early initiation 
of therapy can impact all cause mortality as 
previously discussed and this likely hold true for 
patients with TB and HBV co-infection as well. 
Managing the treatment-experienced patient will be 
the greatest challenge moving forward as more 
patients are on treatment.  Adherence counseling is 
essential to preventing treatment failure but for those 
ndwho fail therapy, strategies should be in place for 2  
rd
and 3 -line regimens.  Deciding who is failing 
treatment is difficult in the absence of viral load 
testing and accurate alternative methods have not yet 
been identified.  For those identified as failing, the 
nd2  line regimens from WHO should be effective 
stparticularly if TDF is used in 1  line regimens.  
Developing third-line regimens represents a 
complex task requiring the availability of expensive 
new ARVs, sophisticated laboratory testing and 
experienced HIV clinicians familiar with these 
drugs.  Zambia has already begun to address the 
need for a cadre of HIV specialists through a new 
Masters degree program in HIV medicine. 
While certain challenges to implementation of these 
guidelines in Zambia and other resource-constrained 
countries exist, the emphasis on earlier treatment and 
a shift toward more potent, less toxic ARVs as part of 
st1  line therapy, provide countries worldwide with the 
opportunity to impact quality of life and overall 
disease burden of this global pandemic. 
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